The in vivo pharmacodynamic results of the combination of IMM47 and PD-1 antibodies showed that in the MC38-hCD24/hPD-L1 tumor cells of the homologous transplanted PD-1 transgenic C57BL/6 mouse model, the combination of IMM47 and the PD-1 antibody Tislelizumab had the best therapeutic effect, and all tumors in mice were eliminated (Fig. 5B). This evidence concerns the gene CD274 and neoplasm.